Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Treprostinil Diolamine

Treprostinil Diolamine API

Treprostinil Diolamine-API

CAS Number: 830354-48-8

Therapeutic Category
Cardiovascular
API Technology
Synthetic
Dose Form
Injectable Solution
Dr Reddy's Development Status
Under-Development
Innovator Brand (USA)
Remodulin

Mechanism of Action

Treprostinil diolamine is a prostacyclin analogue that is used as a medication for the treatment of pulmonary arterial hypertension (PAH) and other forms of cardiovascular disease.

The mechanism of action of treprostinil diolamine is to increase the levels of prostacyclin, a potent vasodilator, in the blood. Prostacyclin acts on the cells that line the blood vessels to relax the smooth muscle and increase blood flow, which helps to improve the symptoms of PAH and other forms of cardiovascular disease.

Additionally, treprostinil diolamine has anti-proliferative and anti-inflammatory effects that help to slow the progression of PAH. It also reduces the formation of blood clots, which is important for preventing serious complications associated with cardiovascular disease.

Indication

Treprostinil diolamine is a medication that is used for the treatment of pulmonary arterial hypertension (PAH) and other forms of cardiovascular disease.

The indications for treprostinil diolamine include:

Pulmonary Arterial Hypertension (PAH): Treprostinil diolamine is used for the treatment of PAH, a serious condition in which the blood pressure in the pulmonary arteries is elevated, leading to difficulty breathing and other symptoms.

Digital Ulcers in Systemic Sclerosis: Treprostinil diolamine is used to treat digital ulcers in patients with systemic sclerosis, a disease that causes thickening and hardening of the skin and connective tissues.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Treprostinil diolamine is used as a treatment option for CTEPH, a type of pulmonary hypertension that occurs after a blood clot has formed in the lungs.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Treprostinil Diolamine API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Treprostinil Diolamine API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Cardiovascular API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.